Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric Subjects with Primary Immunodeficiency Diseases

Trial Profile

Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric Subjects with Primary Immunodeficiency Diseases

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs Immune globulin (Primary) ; Immune globulin (Primary)
  • Indications Immunodeficiency disorders
  • Focus Adverse reactions
  • Sponsors Shire
  • Most Recent Events

    • 24 May 2017 Planned initiation date changed from 30 Apr 2017 to 15 Jun 2017.
    • 05 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top